169 related articles for article (PubMed ID: 20226193)
1. Human framework adaptation of a mouse anti-human IL-13 antibody.
Fransson J; Teplyakov A; Raghunathan G; Chi E; Cordier W; Dinh T; Feng Y; Giles-Komar J; Gilliland G; Lollo B; Malia TJ; Nishioka W; Obmolova G; Zhao S; Zhao Y; Swanson RV; Almagro JC
J Mol Biol; 2010 Apr; 398(2):214-31. PubMed ID: 20226193
[TBL] [Abstract][Full Text] [Related]
2. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
3. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
[TBL] [Abstract][Full Text] [Related]
5. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
[TBL] [Abstract][Full Text] [Related]
6. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
Masuda K; Sakamoto K; Kojima M; Aburatani T; Ueda T; Ueda H
FEBS J; 2006 May; 273(10):2184-94. PubMed ID: 16649995
[TBL] [Abstract][Full Text] [Related]
7. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
8. Engineering fully human monoclonal antibodies from murine variable regions.
Bernett MJ; Karki S; Moore GL; Leung IW; Chen H; Pong E; Nguyen DH; Jacinto J; Zalevsky J; Muchhal US; Desjarlais JR; Lazar GA
J Mol Biol; 2010 Mar; 396(5):1474-90. PubMed ID: 20045416
[TBL] [Abstract][Full Text] [Related]
9. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the horse V(H) repertoire and comparison with the human IGHV germline genes, and sheep, cattle and pig V(H) sequences.
Almagro JC; Martinez L; Smith SL; Alagon A; Estevez J; Paniagua J
Mol Immunol; 2006 Apr; 43(11):1836-45. PubMed ID: 16337682
[TBL] [Abstract][Full Text] [Related]
11. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
12. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
Jung S; Spinelli S; Schimmele B; Honegger A; Pugliese L; Cambillau C; Plückthun A
J Mol Biol; 2001 Jun; 309(3):701-16. PubMed ID: 11397090
[TBL] [Abstract][Full Text] [Related]
13. Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.
Lowe DC; Gerhardt S; Ward A; Hargreaves D; Anderson M; Ferraro F; Pauptit RA; Pattison DV; Buchanan C; Popovic B; Finch DK; Wilkinson T; Sleeman M; Vaughan TJ; Mallinder PR
J Mol Biol; 2011 Feb; 406(1):160-75. PubMed ID: 21167836
[TBL] [Abstract][Full Text] [Related]
14. Antibody humanization by framework shuffling.
Dall'Acqua WF; Damschroder MM; Zhang J; Woods RM; Widjaja L; Yu J; Wu H
Methods; 2005 May; 36(1):43-60. PubMed ID: 15848074
[TBL] [Abstract][Full Text] [Related]
15. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
16. On the domain pairing in chimeric antibodies.
Teplyakov A; Obmolova G; Carton JM; Gao W; Zhao Y; Gilliland GL
Mol Immunol; 2010 Aug; 47(14):2422-6. PubMed ID: 20554002
[TBL] [Abstract][Full Text] [Related]
17. Structural consequences of humanizing an antibody.
Holmes MA; Foote J
J Immunol; 1997 Mar; 158(5):2192-201. PubMed ID: 9036965
[TBL] [Abstract][Full Text] [Related]
18. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering.
Pelat T; Bedouelle H; Rees AR; Crennell SJ; Lefranc MP; Thullier P
J Mol Biol; 2008 Dec; 384(5):1400-7. PubMed ID: 18976662
[TBL] [Abstract][Full Text] [Related]
19. Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms.
Fennell BJ; Darmanin-Sheehan A; Hufton SE; Calabro V; Wu L; Müller MR; Cao W; Gill D; Cunningham O; Finlay WJ
J Mol Biol; 2010 Jul; 400(2):155-70. PubMed ID: 20450918
[TBL] [Abstract][Full Text] [Related]
20. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
